Antibody

57개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved57 programs
AntibodyLimited DatastaleGerman Cancer Research CenterPhase 2

CC-1 and Toczilizumab (CC-1 and Toczilizumab)

Lung Cancer Squamous Cell · Lung Cancer Squamous Cell

#LungCancerSquamousCell#Antibody#Phase2#monoclonal-antibody#German
Trials 1Status Discontinued
AntibodyLimited DatastaleTaizhou Mabtech Pharmaceutical …Phase 1

CMAB819 (CMAB819)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase1#monoclonal-antibody#Taizhou
Trials 1Status Discontinued
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Cetuximab (Camrelizumab and Cetuximab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Chemotherapy (Camrelizumab and Chemotherapy)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab+cetuximab+chemotherapy (Camrelizumab+cetuximab+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

Dalpiciclib+cetuximab (Dalpiciclib+cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Dalpicilib combined with cetuximab (Dalpicilib combined with cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Boehringer
Trials 1Status Recruiting
AntibodyLimited DatastaleHookipa Biotech GmbHPhase 2

pembrolizumab (Keytruda, HB-202 / HB-201 alternating intravenous administration + pembrolizumab.)

HPV-Related Squamous Cell Carcinoma · HPV-Related Squamous Cell Carcinoma

#HPV-RelatedSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Hookipa
Trials 1Status Active
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#HeadandNeckCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

INDUCTION CTx (TPF, INDUCTION CTx, INDUCTION CTx(TPF)+(RT+CETUXIMAB))

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
AntibodyLimited DatastaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#monoclonal-antibody#Merck
Trials 1Status Recruiting
AntibodyLimited DatastaleGroupe Oncologie Radiotherapie …Phase 3

Ligufalimab (Ligufalimab)

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · Squamous Cell Carcinoma Head and Neck Ca

#SquamousCellCarcinomaHeadandNeck#Antibody#Phase3#monoclonal-antibody#Groupe
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab (MRG003 combined with Pucotenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab+Cisplatin (MRG003 combined with Pucotenlimab+Cisplatin)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 3

pembrolizumab (Keytruda, PD-1 mAb, Pembrolizumab/Finotonlimab, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#monoclonal-antibody#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Recruiting
AntibodyLimited DatastaleDana-Farber Cancer InstitutePhase 2

Pembroluzimab (Pembroluzimab)

HPV-positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma · HPV-positive Oropharyngeal Squamous Cell

#HPV-positiveOropharyngealSquamou#Antibody#Phase2#monoclonal-antibody#OropharyngealSquamousCellCarcino+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 3

Petosemtamab (Petosemtamab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Merus
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 2

pembrolizumab (Keytruda, Petosemtamab + Pembrolizumab)

Lung Cancer - Non Small Cell Squamous; Lung Cancer - Non Small Cell Non-Squamous · Lung Cancer - Non Small Cell Squamous

#LungCancer-NonSmallCellSquamous#Antibody#Phase2#monoclonal-antibody#LungCancer-NonSmallCellNon-Squam+1
Trials 1Status Recruiting
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting

2 / 3 pages

← PreviousNext →